Alps Group Inc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $45.3M
- Price
- $0.2724
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.89%
- Volume
- 2.1K
About
Alps Group Inc. operates as a comprehensive biotechnology firm, delivering a wide array of services ranging from groundbreaking research and development to direct medical care and health optimization initiatives, with a primary focus on cutting-edge therapeutic solutions. The organization is committed to cultivating a just and balanced healthcare system, ensuring broad availability of early detection, disease prevention, and individualized treatment approaches.
Quick stats
Shares outstanding166.4M
Computed float48.4M
Float / shares29.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002025774
Websitehttps://alps-holdings.com
AI Summary
AI-generated1/11
standardmixedearnings
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
Alps Group reported fiscal 2026 revenue of $4.9 million, representing a 44% increase year-over-year, driven by growth in cellular therapy, medical testing, and aesthetics services. The company highlighted its first full year trading on the Nasdaq Global Market following its business combination with Globalink Investment Inc.
Despite the top-line growth, gross margins compressed to 32% from 39% due to a revenue mix shift towards lower-margin aesthetic services. The company narrowed its net loss to $2.1 million from $2.6 million in the prior year, though administrative expenses increased to $3.5 million, largely due to $1.16 million in professional fees tied to the business combination.
Operationally, Alps appointed a new CFO and added a former EY partner to its board while advancing its MyImmune NK cell therapy program. However, the balance sheet reflects a capital deficiency of $3.2 million with cash ending the year at just $607,000 against a $2.6 million operating cash burn.
Red flags
- Gross margin declined to 32% from 39% due to revenue mix shift
- Balance sheet reflects capital deficiencies of $3.2 million (negative equity)
- Cash position of $607k is insufficient to cover annual operating cash burn of $2.6M
- Professional fees of $1.16M for business combination weighed on administrative expenses